#ExpleoSolutions Q3 concall highlights

Like & Retweet for better reach !

Numbers Update -

1. The revenue for the quarter was 120 cr up by 9% QoQ

2. EBITDA stood at Rs 187 million vs Rs 137 million in Q3FY21, up by 36.6%
3. PAT was at Rs 116 million vs Rs 125 million in Q3FY21
The 9M revenue stood at 293 cr up by 31.3% compared to same period last year
The 9M PAT was up by 12.3%

4. Net cash position stood at 163 cr
Business Updates -

1. The company sees demand and traction also on the renewal side
ER&D business did well in the year 2021 and also the Aerospace business did well.

2. Attrition remains the challenge
3. The projects are anywhere between 12 - 18 months the rates are changed during the renewal.

4. The company will not just focus on testing as a solely will be doing testing with automation, testing with DevOps etc
5. BFSI is the strength of the company but the strategy is also to focus on other verticals in healthcare, EdTech etc

6. The company will be back to EBITDA of 18% - 19% after within a few quarters.
7. Engineering business has lower margins, Mechanical engineering runs at lower margins whereas the product and digital runs at higher margins, as of now India business is more towards the mechanical side.
8. The digital business has grown from 9% two years back to 35%, expecting this business to grow faster than the traditional testing services business and this number to be around 50% during the course of CY 2022.
Merger Update-

1. The company has received approval from SEBI, waiting for the court hearing.

2. Expecting to get the first NCLT approval in couple weeks

3. The merger procedure to be completed around July 2022
4. This merger will bring Tech + Engineering capabilities

Margins Dip update -

1. The margins were dipped due to sale of licences from the partnership directly to the customers which is a low margin business than services business.
2. Increase in salaries also put pressures on the margins

Employees Update-
1. Added over 360 people during the Quarter

2. The company Has over 4000 employees across all entities and expects this number to be 5000 before the end of CY 2022.
3. The listed entity has over 2100 employees, the Bangalore entity has over 900 employees and the Pune entity has close to 1100 employees.

4. Expects to reach 10,000 employee mark in 2025

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 13
#CDSL Q3 2022 ConCall Highlights

Like & Retweet for better reach !

Numbers Update-

1. Demat accounts across both the depositories stands at 8.4cr,

2. CDSL has 70% of the share at 5.8 cr accounts.
3. The revenue for the Q3 was 151 cr up by more than 50% YoY

4. Number of Demat AC opened as of Dec 21 is more than 29 Lakhs.

5. EBITDA for the quarter stood at 87.42 cr and PAT stood at 63.76 cr

6. The revenue from transaction charges stood at 52.7 cr
7. CVL contributed 33.6 cr of the revenues

8. IPO charges contributed 23.41 cr of revenues

9. Annual issuer charges contributed around 28.98 cr of revenues

10. The 9M debtors provisions stands around 8 cr compared to 7.34 cr previous year.
Read 8 tweets
Feb 13
#LatentViewAnalytics Q3 2022 Concall Highlights

Like & Retweet for better reach !

Numbers Update-

1. The revenue for Q3 was 107 cr up by 13.7% QoQ an 37.7% YoY

2. EBITDA stood at 32.2 cr for Q3 and EBITDA margins stood at 29.9%, giving the industry highest margins.
3. PAT for Q3 was 49.9 cr and PAT margins stood at 44.2%

4. Technology sector contributes around 67% of revenues

5. CPG Contributes 15% of the revenues and other contribute around 18% of revenue.

6. 6 clients were added in this quarter
7. Utilisation stands around 80% - 85%

Business Updates-

1. Latent View Analytics is a pure play Analytics company and also little towards consulting and data engineering, Business analytics is 60% of the business.
Read 14 tweets
Feb 13
#Deepaknitrite Q3 2022 Concall Highlights 🧪🧪

Operational Highlights

1. The revenue for the quarter was ₹1748 cr it was up 41% YoY as against ₹1240 Cr in same quarter previous year
2. EBITDA margins stood at 22% translation to EBITDA of ₹378 Cr
Continued robust revenue momentum was fuelled by solid growth trajectory in Phenolics
3. In Q3 FY22, the company has achieved highest ever top line in a quarter, both on standalone and consolidated basis

4. Business segments are interwoven, this means that if prices of
Read 13 tweets
Feb 13
#DivisLaboratories Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. Revenues for the quarter stood at ₹2510 Cr (46% growth YoY).

2. PBT for the quarter stood at ₹1034 Cr (61% growth YoY).
3. Exports contributed to 92% of revenues for the quarter. Europe and the US contributed to 79% of revenues .

4. Generics contributed to 40% and Custom Synthesis contributed to 60% of revenues for the quarter. Nutraceutical business contributed ₹166 Cr for the quarter.
5. They have capitalized ₹196 Cr of capex during the quarter and ₹762 Cr for 9 months. They expect another ₹100 Cr to be capitalized by the end of the financial year. Capex in the new SEZ accounted for ₹368 Cr.
Read 13 tweets
Feb 13
#ErisLifesciences Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. Revenues for the quarter stood at ₹332 Cr (7% growth YoY).
2. EBITDA for the quarter was at ₹122 Cr (13.5% growth YoY). EBITDA margin for the quarter was at 37%. PAT for the quarter was ₹101 Cr (12% growth YoY)
3. The Guwahati facility contributed to 80% of the revenues for the quarter. Operating cash flow to EBITDA stood at 73% for the 9 months.
Read 17 tweets
Feb 13
#StridesPharma Sciences Q3 FY22 concall highlights 💊💊

1. Revenues for the quarter stood at ₹796 Cr (5% decline YoY).

2. Gross margins decline by 840 bps YoY.
3. Gross margin compression is due to product mix and they had inventory of increased RM prices which were adjusted to the lower realizations they received.
4. They are seeing an uptick in opportunities in the regulated markets and are expecting to see a sequential recovery from here. They believe that some of the products that they let go due to increased competition is playing in their favor.
Read 15 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!